Compare Roundhill NVDA WeeklyPay ETF (NVDW) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill NVDA WeeklyPay ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? Roundhill NVDA WeeklyPay ETF trades at $34.27 (market cap $116.41M), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 43.1× Roundhill NVDA WeeklyPay ETF's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Roundhill NVDA WeeklyPay ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Roundhill NVDA WeeklyPay ETF for 52 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| NVDW | TVTX | |
|---|---|---|
Market Cap | $116.41M | $5.02B |
Volume | 58,937 | 2,060,842 |
Sector | Income / Options Overlay | Health |
52-Week High | $52.33 | $67.52 |
52-Week Low | $31.88 | $26.79 |
Typical Hold Time | 52 Days | 0 Days |
Enterprise Value | — | $5.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDW trades at $36.64 with minimal daily movement (+0.14%). Technical indicators show a bearish trend with strong sell signals from moving averages, though RSI suggests potential oversold conditions. The ETF generates weekly dividend income from Nvidia exposure but carries leverage risks. Recent news highlights its high-yield potential amid Nvidia's strong earnings performance.
The outlook remains cautious due to leveraged structure and dependency on Nvidia volatility. While weekly dividends offer income appeal, NAV erosion during Nvidia downturns presents significant risk. Investors should weigh high yield potential against elevated volatility exposure in this specialized income vehicle.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Roundhill NVDA WeeklyPay ETF
NVDW is an actively managed ETF that seeks to provide weekly distributions and returns equal to 1.2 times (120%) the calendar week performance of Nvidia (NVDA) common shares. It combines modest leverage with a high-frequency payout schedule, designed for investors who want amplified exposure to Nvidia alongside a consistent weekly income stream.
Read more on NVDW →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
